All In Biotech

Drug Trial Radar · NCT03990649

Study of TAK-935 as an Adjunctive Therapy in Adult Participants With Complex Regional Pain Syndrome (CRPS)

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 as an Adjunctive Therapy in Adult Subjects With Chronic Complex Regional Pain Syndrome

Last checked: Nov 20, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

24

Actual

Start

Jul 23, 2019

Primary completion

Jun 29, 2020

Study completion Oct 28, 2020

Sponsor

Lead sponsor
Millennium Pharmaceuticals, Inc.Takeda (TAK)
Sponsor type
Industry
First posted
Jun 19, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate the effect of soticlestat (TAK-935) on calculated 24-hour average pain intensity by the numeric pain scale (NPS).

Conditions

  • Complex Regional Pain Syndrome

Interventions

  • SoticlestatDrug

    Soticlestat tablets

  • PlaceboDrug

    Soticlestat matching placebo tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Mean 24-Hour Pain Intensity as Assessed by NPS Score to the End of Part ATime frame: Baseline and Week 15

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • St Pancras Clinical Research

    London, England, United Kingdom

  • Lancashire Teaching Hospitals NHS Foundation Trust

    Preston, England, United Kingdom

  • University Hospital Southampton NHS Foundation Trust

    Southampton, England, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.